A Biotech 'Cure' | GenomeWeb

A Biotech 'Cure'

Drugmaker GlaxoSmithKline has had a "miserable" year, says Forbes' Robert Langreth. Sales are "stagnant"; it's facing the loss of its patent on asthma drug Advair; its diabetes treatment, Avandia, is off the market in Europe and use of the drug was restricted in the US after the company was accused of minimizing data that show it caused heart problems; and in October, it paid $750 million to settle charges that it produced tainted drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.